We describe a generic protocol for the overproduction and purification of recombinant proteins in Escherichia coli. The strategy utilizes a dual His 6 -maltose binding protein (HisMBP) affinity tag that can be removed from the target protein by digestion of the fusion protein at a designed site by tobacco etch virus protease. The MBP moiety serves to enhance the solubility and promote the proper folding of its fusion partners, and the polyhistidine tag facilitates its purification to homogeneity. This protocol is divided into three stages, each of which takes approximately 1 week to complete: (i) construction of a HisMBP fusion vector; (ii) a pilot experiment to assess the yield and solubility of the target protein; and (iii) the large-scale production and purification of the target protein.
INTRODUCTION
Affinity tags and other types of genetically engineered fusion partners are widely employed as tools in molecular biology. Although these were originally developed to facilitate the detection and purification of recombinant proteins, in recent years it has become clear that certain tags can also improve the yield, enhance the solubility and even promote the proper folding of their fusion partners. The strengths and weaknesses of various tags have been reviewed recently [1] [2] [3] . As the insolubility of recombinant proteins, particularly in Escherichia coli, is a major bottleneck in the production of bioactive material for structural and functional studies 4 , the utilization of solubility-enhancing tags to avoid the formation of insoluble protein aggregates has been rapidly gaining in popularity.
Although many proteins that are highly soluble when overproduced in E. coli have been reported to possess solubilityenhancing qualities as fusion partners, in most cases the evidence to support these claims is scant 1 . Not all highly soluble proteins can function as solubility enhancers, so it is a mistake to assume that these two properties can be equated. Nevertheless, two proteins with a very well-established ability to function as solubility enhancers are E. coli maltose binding protein (MBP) and NusA 5, 6 . The mechanisms by which these two proteins enhance the solubility of their fusion partners are not well understood but may be similar 7 .
Among the known solubility-enhancing fusion partners, MBP is unique in that it is also a natural affinity tag. MBP fusion proteins can be purified using amylose affinity chromatography 8 . However, we and others have observed that MBP fusion proteins often do not bind efficiently to amylose resin and that even when they do, this type of affinity chromatography does not routinely produce samples of satisfactory purity 3, 9, 10 .
We previously demonstrated that adding a polyhistidine tag (His 6 ) to the N-terminus of MBP does not interfere with its ability to promote the solubility and proper folding of its fusion partners 11 . Immobilized metal affinity chromatography (IMAC) utilizing His 6 -tagged proteins has proven to be a very powerful method for protein purification and is routinely utilized by all of the large structural-genomics centers. Hence, by combining the His 6 and MBP tags, it is possible to exploit the unique benefits of each. The MBP moiety serves to enhance the solubility and promote the proper folding of its fusion partners, and the His tag facilitates their purification to homogeneity via an entirely generic protocol.
Experimental design
This protocol describes how to (i) construct a dual His 6 -MBP (HisMBP)-tagged fusion protein expression vector by Gateway recombinational cloning; (ii) conduct a pilot experiment to assess the yield and solubility of the recombinant protein both before and after intracellular processing of the fusion protein by tobacco etch virus (TEV) protease; and (iii) purify the target protein on a large scale for structural or functional studies.
Gateway cloning technology utilizes the site-specific recombination reactions that mediate the integration and excision of bacteriophage lambda into and from the E. coli chromosome, respectively. For more detailed information on this system, the investigator is encouraged to consult the technical literature supplied by Invitrogen (http://www.invitrogen.com/content/ online%20seminars/gateway/gatewayhome.html). Gateway recombinational cloning, which is featured in this protocol, greatly facilitates the construction of HisMBP fusion vectors by eliminating the need for restriction endonucleases and DNA ligase. However, alternative methods of cloning, such as ligation-independent cloning, may also be used provided that suitable vectors are available 12 .
To construct a HisMBP fusion vector by recombinational cloning, it is necessary to generate a PCR amplicon wherein the open reading frame (ORF) of interest is flanked by attB1 and attB2 recombination sites on its N-and C-termini, respectively. A recognition site for TEV protease is also added between the attB1 site and the N-terminus of the ORF. The PCR amplification is p u o r G g n i h s i l b u P e r u t a Nperformed with two overlapping N-terminal primers and a single C-terminal primer, as outlined in Figure 1 . Two gene-specific primers (N1 and C) are required for each ORF. The overlapping N-terminal primer (N2) can be used to add the attB1 recombination site to the N-terminus of any ORF to which the TEV protease recognition site has already been added.
To create the HisMBP fusion vector, the PCR product is first recombined by Gateway cloning into the donor vector pDONR221 to yield an entry clone intermediate (BP reaction), and then into pDEST-HisMBP (LR reaction) to generate the HisMBP fusion protein expression vector (Fig. 2) . The BP and LR reactions are analogous to the recombination reactions that mediate integration and excision, respectively, of the bacteriophage lambda genome from the E. coli chromosome. Both positive (antibiotic resistance) and negative (deletion of the lethal ccdB gene) selections are utilized to ensure that the correct recombination product is obtained with high efficiency.
Before large-scale cell growth and purification of the target protein, it is advisable that a small-scale pilot experiment be performed to gather some important information. First, is the solubility of the HisMBP fusion protein adequate? Second, can the fusion protein be cleaved efficiently by TEV protease? Third, does the target protein remain soluble after it is separated from the HisMBP moiety? If the answers to any of these three questions is negative, then there is little point in scaling up the procedure without first attempting some troubleshooting (see Table 1 ). The latter two questions are answered using separate plasmid vectors to express TEV protease along with the fusion protein in E. coli. The In the first step (BP reaction), the PCR amplicon ( Fig. 1) is recombined with the donor vector pDONR221 to give rise to an entry clone intermediate. The entry clone can be recovered from kanamycin-resistant transformants of DH5a cells, if desired (see Step 8) . Alternatively, the second recombination reaction (LR reaction), which involves the transfer of the ORF from the entry clone into the destination vector (pDEST-HisMBP), can be performed immediately after the BP reaction has been completed, thereby bypassing the isolation of an entry clone intermediate, as described in this protocol (Steps 4-15) .
production of the fusion protein substrate and the production of TEV protease are induced by isopropyl-b-D-thiogalactopyranoside (IPTG) and anhydrotetracycline, respectively. We have observed that delaying the induction of TEV protease for 2 h after induction of the fusion protein often improves the solubility of the target protein after TEV digestion in vivo 13 . If required, antibiotics can be added to a final concentration of 30 mg ml À1 for kanamycin, 30 mg ml À1 for chloramphenicol or 100 mg ml À1 for ampicillin. LB agar plates Add 12 g bacto agar to 1 l LB medium before autoclaving. To prepare plates, allow medium to cool until flask or bottle can be held in hands without burning, then add 1 ml appropriate antibiotic stock(s), mix by gentle swirling and pour or pipette approximately 30 ml into each sterile Petri dish (100 mm diameter). The final concentration of kanamycin should be 30 mg ml À1 , and the final concentration of ampicillin should be 100 mg ml À1 . PCR primer design The sequence of primer N2 is constant, as indicated in Figure 1 . The 5¢ ends of primers N1 and C, encompassing the TEV protease recognition site and attB2 recombination site, respectively, are also constant. However, the 3¢ ends of the latter two primers will vary according to the ORF to be amplified. In general, the variable regions should be 20-25 nt in length. It is advisable to avoid dyad symmetry at the 3¢ ends. PCR optimization If the PCR does not work when all three primers are added to the reaction at once, as described above, then it can be carried out in two steps instead, using primers N1 and C in the first step and primers N2 and C in the second step. The PCR amplicon from the first step is used as the template for the second PCR. Note, the PCR can be modified in numerous ways to optimize results, depending on the nature of the template and primers. See ref. 15 (vol. 2, chapter 8) for more information. Preparation of competent cells Electrocompetent cells exhibit the highest transformation efficiency. However, transformation by electroporation requires expensive, specialized apparatus (the electroporator) that may not be available in every laboratory. Detailed protocols for the preparation of electrocompetent cells and electrotransformation can be obtained from the manufacturer (e.g., Bio-Rad, BTX, Eppendorf). In short, grow the cells in 1 l LB medium (with appropriate antibiotics) to mid-log phase (OD 600 nm approximately 0.5) and then chill on ice. Pellet the cells at 4 1C, re-suspend in 1 l ice-cold water and pellet again. Repeat the wash with water (two to three times), re-suspend the cells in 3-4 ml 10% glycerol, divide into 50-ml aliquots and then freeze immediately in a dry-ice/ethanol bath. Store the electrocompetent cells at À80 1C. Before electrotransformation, thaw the cells on ice and mix with 10-100 ng DNA (e.g., a plasmid vector or a Gateway reaction). Place the mixture in an ice-cold electroporation cuvette and electroporate according to manufacturer's recommendations (e.g., a 1.5-kV pulse in a cuvette with a 1-cm gap). Add 1 ml LB medium to the cells and shake (250 r.p.m.) at 37 1C for 1 h. Spread 5-200 ml cells on an LB agar plate containing appropriate antibiotic(s). For the routine Gateway cloning procedures described in this protocol, high-efficiency (i.e., more than 1 Â 10 7 colony forming units per mg À1 ) chemically competent DH5a cells (Invitrogen) can be used instead of electrocompetent cells, according to the manufacturer's instructions. Note that special cells with a CcdB-resistant gyrA allele (e.g., DB3 and DB5) or cells that have otherwise been rendered resistant to the DNA gyrase poison CcdB (e.g., One Shot CcdB Survival cells) must be used to propagate pDONR221 and pDEST-HisMBP. It will be necessary to prepare competent BL21-Pro cells containing pRK603 for the pilot experiment. Electrocompetent cells are recommended for this purpose owing to the inherently low transformation efficiency of E. coli BL21 cells. 2| Run the PCR using the program shown in Table 2 . m CRITICAL STEP The polymerization time at 72 1C and the annealing temperature may need to be adjusted, depending on the target and primer sequences, but the conditions given here should be applicable in most cases. See REAGENT SETUP for further optimization details.
MATERIALS
3| Examine the product(s) of the PCR by agarose gel electrophoresis (1% TAE agarose) and ethidium bromide staining, and purify the PCR product to remove residual attB primers using a QIAquick gel extraction kit, according to the manufacturer's instructions. ' PAUSE POINT The purified PCR product can be kept frozen at À20 1C for at least 1 month if desired. 6| Remove a 5-ml aliquot from the reaction mix and add it to 0.5 ml proteinase K solution, included in the Gateway cloning kit. Incubate for 10 min at 37 1C.
7| Transform 2 ml of the reaction mix from Step 6 into 50 ml competent DH5a cells using standard laboratory techniques 15 .
8| Pellet the cells by centrifugation (3,000g for 15 min), gently re-suspend the pellet in 100-200 ml LB medium and spread on an LB agar plate containing 100 mg ml À1 kanamycin, the selective marker for pDONR221. Incubate the plate at 37 1C overnight. Entry clones can be recovered from these colonies in the event that no transformants are obtained after the subsequent LR reaction. 11| Add 1 ml proteinase K solution to stop the reaction, and incubate for 10 min at 37 1C.
12| Transform 2 ml of the reaction mix into 50 ml competent DH5a cells using standard techniques 15 . 13| Pellet the cells by centrifugation (3,000g for 15 min), gently re-suspend the pellet in 100-200 ml LB medium and spread on an LB agar plate containing 100 mg ml À1 ampicillin, the selective marker for pDEST-HisMBP. Incubate the plate at 37 1C overnight.
? TROUBLESHOOTING 14| Select several ampicillin-resistant colonies and use them to inoculate 5 ml LB medium containing 100 mg ml À1 ampicillin. Shake the cultures overnight at 250 r.p.m. and 37 1C.
15| Purify the plasmid DNA from each saturated overnight culture using a QIAquick spin miniprep kit, according to the manufacturer's instructions. Perform sequence analysis to confirm that the nucleotide sequence of the putative clones is correct. ' PAUSE POINT Plasmid DNA can be stored at À20 1C for several months.
Expression and purification of HisMBP fusion proteins 16| To carry out a pilot expression experiment and TEV protease digest, proceed according to option A. The purpose of the pilot experiment is to assess the solubility of the HisMBP fusion protein in E. coli, to gauge how efficiently it is cleaved by TEV protease and to ascertain whether the target protein is likely to remain soluble after the HisMBP tag is removed by TEV protease. This information can be very valuable in deciding whether it is worthwhile to scale up the process. To perform large-scale cell growth and protein purification, proceed as described in option B. (xiv) Prepare samples of the soluble intracellular protein from the '+' and 'À' cultures (S+ and SÀ, respectively) for SDS-PAGE by mixing 50 ml of each supernatant from Step (xiii) with 50 ml 2Â SDS-PAGE sample buffer containing 10% (vol/vol) b-mercaptoethanol. (xv) Heat the TÀ, T+, SÀ and S+ protein samples at 90 1C for approximately 5 min and then spin them at maximum speed in a microcentrifuge for 5 min. (xvi) Assemble the SDS gel in the electrophoresis apparatus, fill with SDS-PAGE running buffer, load the samples (10 ml each) and carry out the electrophoretic separation according to standard lab practices 14 . Load T and S samples from each culture ('+' and 'À') in adjacent lanes to allow easy assessment of solubility. Molecular weight standards can also be loaded on the gel if desired. ' PAUSE POINT Freeze the cell pellet at À80 1C until further use (this may be for as long as several months). (vii) Re-suspend the cell pellet in 50 mM sodium phosphate buffer, (pH 7.7 at room temperature), 150 mM sodium chloride and 25 mM imidazole containing complete EDTA-free protease inhibitor cocktail tablets (according to the manufacturer's instructions), using at least 10 ml g À1 wet cell paste. (viii) Lyse the cell suspension using the APV-1000 homogenizer at 10,000-11,000 psi for two to three rounds and centrifuge the disrupted cell suspension for at least 30 min at 15,000g. Filtering through 0.45-mm polyethersulfone membrane helps to remove residual particulates before chromatography. (ix) Apply the supernatant to a column of Ni-NTA resin equilibrated in 50 mM sodium phosphate buffer (pH 7.7), 150 mM sodium chloride and 25 mM imidazole. Wash the column with this buffer until a stable baseline is reached and then elute the bound fusion protein (HisMBP-passenger) with a linear gradient over 10 column volumes into 50 mM sodium phosphate buffer (pH 7.7), 150 mM sodium chloride and 250 mM imidazole. The fusion protein usually elutes between 100 and 150 mM imidazole. Identify fractions containing the fusion protein by SDS-PAGE 15 . (x) Pool the peak fractions containing fusion protein and concentrate the sample approximately tenfold using an Amicon stirred ultrafiltration cell fitted with a YM30 membrane according to the manufacturer's instructions. Remove any precipitate by centrifuging at 5,000g for 10 min. (xi) Add His 6 -TEV protease (1 OD 280 TEV protease per 100 OD 280 fusion protein) to the supernatant from Step 16B(x). Digest overnight at 4 1C. The progress of the cleavage reaction can be monitored by SDS-PAGE if desired 15 .
? TROUBLESHOOTING (xii) Dilute the digest with 50 mM phosphate buffer (pH 7.7) and 150 mM sodium chloride buffer to reduce the imidazole concentration to 25 mM. Apply the TEV protease digestion products from Step 16B(xi) to a second Ni-NTA column under the same conditions used during application to the first column. This step serves to absorb the TEV protease, the HisMBP moiety and any residual uncleaved fusion protein to the column. (xiii) Collect the unbound (flow-through) fractions that pass through the Ni-NTA column, which should contain the target protein free of the HisMBP tag, and check the purity by SDS-PAGE 15 .
? TROUBLESHOOTING (xiv) Concentrate the protein sample from Step 16B(xiii) approximately tenfold using the Amicon stirred cell fitted with a YM10 membrane according to the manufacturer's instructions and add the reducing agent TCEP to a final concentration of 2 mM. The TCEP will prevent the formation of intermolecular disulfide bonds. (xv) Apply 2 ml concentrated sample onto a Hiprep 26/60 Sephacryl S-100 HR column equilibrated with gel filtration buffer.
m CRITICAL STEP The volume of the sample loaded should be no more than 4% of the column volume and contain no more than 50 mg protein. (xvi) Pool the peak fractions of pure protein from the gel filtration column(s) and concentrate to 1-5 mg ml À1 using the Amicon stirred cell fitted with a YM10 membrane according to the manufacturer's instructions. (xvii) Filter through a 0.2-mm syringe filter, prepare 0.5-1-ml aliquots and flash-freeze with liquid nitrogen.
' PAUSE POINT Store at À80 1C indefinitely.
TIMING
Steps 1-3, amplification of ORF by PCR: 1.5 h Steps 4-8, creating ORF-entry vector by recombinational cloning: 4-16 h Steps 9-15, cloning HisMBP-ORF vector by recombinational cloning: 3 d
Step 16A, pilot expression of HisMBP fusion protein: 3-4 d
Step 16B, large-scale expression and purification of HisMBP fusion protein: 5 d
? TROUBLESHOOTING Troubleshooting advice can be found in Table 1 .
ANTICIPATED RESULTS
The pilot expression experiment and TEV protease digest may yield a range of different results, depending on the nature of the passenger protein. The most common results are illustrated in Figure 3 , using three different passenger proteins as examples. have previously been shown to be very insoluble when expressed in an unfused state and/or as glutathione-Stransferase fusion proteins in E. coli 6, 16 . The most desirable outcome is exemplified by the HisMBP-DHFR fusion protein. In this case, the DHFR is efficiently solubilized by fusing it to HisMBP. Moreover, a significant fraction of the DHFR remains soluble in the extract after intracellular processing of the fusion protein by TEV protease, which is consistent with the existence of properly folded protein, and a similar result can be expected during scale-up and purification. Note, however, that unlike the other examples shown here, the HisMBP-DHFR fusion protein is not digested to completion. This indicates that more than the usual amount of enzyme and/or a longer digest may be required to cleave this substrate to completion in vitro.
The HisMBP-TIMP fusion protein is also mostly soluble, but none of the cleaved TIMP remains soluble after intracellular processing. This may indicate that the TIMP is improperly or incompletely folded. Alternatively, proteins that have a tendency to aggregate in their native states may also exhibit this type of behavior.
In the case of HisMBP-luciferase, only a very small fraction of the fusion protein is soluble. Not surprisingly, therefore, virtually none of the luciferase is soluble after intracellular processing. This example is included to demonstrate that not all passenger proteins can be rendered soluble by fusing them to HisMBP.
LcrH, a virulence factor encoded by the plague-causing bacterium Yersinia pestis, is used here as an example to illustrate the generic purification process based on two successive IMAC steps (Fig. 4) . Before this, an intracellular processing experiment was conducted on the HisMBP-LcrH fusion protein that yielded results similar to those obtained with the HisMBP-DHFR fusion protein (data not shown). After the first IMAC column, the purity of the fusion protein is typically in the range of 70-80%. As any endogenous proteins that bind non-specifically to the resin during the first IMAC step also do so during the second round of IMAC, purity improves significantly at this stage.
We recommend using a gel filtration column as a final polishing step to exchange the protein into an appropriate buffer for the intended application and to detect and remove any high-molecular-weight aggregates that may be present. Occasionally some contaminants will persist after the second IMAC step. These may be chaperones (e.g., GroEL) or endogenous proteins with natural affinity for the target protein. Chaperones can sometimes be released from the target protein by incubating it with ATP and magnesium, but because they bind selectively to proteins that are incompletely or improperly folded, their presence as contaminants is never a good sign. In addition, in some cases, the HisMBP moiety may stick (bind non-covalently) to the target protein after digestion of the fusion protein by TEV protease. It is unclear exactly why this happens, but it may be related to the mechanism of solubility enhancement. When contaminants persist after the second IMAC step, additional forms of chromatography (e.g., ion exchange 17 ) may be required to produce a homogeneous sample.
Not all proteins can be rendered soluble by fusing them to HisMBP, and of those that can, some will precipitate after digestion of the fusion protein by TEV protease. In addition, some fusion proteins are resistant to digestion by TEV protease. Nevertheless, the available evidence indicates that many aggregation-prone proteins can be recovered in a properly folded, biologically active form in this manner. For instance, in one recent study involving 632 HisMBP fusion proteins 18 , 80% were observed to be soluble. Approximately 70% of the soluble fusion proteins could be cleaved efficiently by TEV protease. Fifteen of the target proteins precipitated upon removal of the HisMBP moiety by TEV protease. The overall success rate was 42%. 
